Microbiome in the setting of burn patients: implications for infections and clinical outcomes.
Silvia CorcioneTommaso LupiaFrancesco G De Rosanull nullPublished in: Burns & trauma (2020)
Burn damage can lead to a state of immune dysregulation that facilitates the development of infections in patients. The most deleterious impact of this dysfunction is the loss of the skin's natural protective barrier. Furthermore, the risk of infection is exacerbated by protracted hospitalization, urinary catheters, endotracheal intubation, inhalation injury, arterial lines and central venous access, among other mainstays of burn care. Currently, infections comprise the leading cause of mortality after major burn injuries, which highlights the improvements observed over the last 50 years in the care provided to burn victims. The need to implement the empirical selection of antibiotic therapy to treat multidrug-resistant bacteria may concomitantly lead to an overall pervasiveness of difficult-to-treat pathogens in burn centres, as well as the propagation of antimicrobial resistance and the ultimate dysregulation of a healthy microbiome. While preliminary studies are examining the variability and evolution of human and mice microbiota, both during the early and late phase burn injury, one must consider that abnormal microbiome conditions could influence the systemic inflammatory response. A better understanding of the changes in the post-burn microbiome might be useful to interpret the provenance and subsequent development of infections, as well as to come up with inferences on the prognosis of burn patients. This review aims to summarise the current findings describing the microbiological changes in different organs and systems of burn patients and how these alterations affect the risks of infections, complications, and, ultimately, healing.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- multidrug resistant
- newly diagnosed
- antimicrobial resistance
- prognostic factors
- palliative care
- oxidative stress
- metabolic syndrome
- stem cells
- escherichia coli
- mesenchymal stem cells
- type diabetes
- patient reported outcomes
- cardiac arrest
- pseudomonas aeruginosa
- lipopolysaccharide induced
- bone marrow
- drug resistant
- quality improvement
- chronic pain
- human health